Bristol Myers Squibb stock: Analysts set USD 64.88 target for Bristol Myers Squibb stock
Published on 10/22/2026 at 18:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- On October 20, 2026, thirty analysts set a USD 64.88 average target for Bristol Myers Squibb.
- Second-quarter 2026 revenue reached USD 12.97 billion, up 5.70 percent year over year.
- Bristol Myers Squibb stock costs EUR 55.98 at Lang & Schwarz on October 22, 2026 at 6:19 p.m. CEST.
Bristol Myers Squibb (ISIN US1101221083) has an average analyst target of USD 64.88, based on thirty analysts as reported by MarketBeat on October 20, 2026. At Lang & Schwarz, the stock was trading at EUR 55.98 on October 22, 2026 at 6:19 p.m. CEST.
Revenue provides the earnings anchor
Bristol Myers Squibb reported USD 12.97 billion in revenue for the second quarter of 2026, up 5.70 percent from the same period a year earlier, according to MarketBeat. The same report cited quarterly earnings per share of USD 2.04 against a USD 1.60 consensus estimate, a USD 0.44 difference.
What does the price position say?
The euro quotation sits within a wide primary-market range. On the NYSE, Bristol Myers Squibb traded at USD 62.80 on October 22, 2026 at 12:27 p.m. EDT, while the 52-week range was USD 42.52 to USD 68.64. The share price was 8.51 percent below that high, calculated from the same USD quotation.
Valuation and the next date
The NYSE quotation carried a market capitalization of USD 128.3 billion and a price-to-earnings ratio of 13.84 on October 22, 2026. MarketBeat reported that third-quarter 2026 results were scheduled for October 29, 2026, before the market opened, with consensus revenue of USD 12.74 billion.
Comparison with peers
Bristol Myers Squibb: price-to-earnings ratio 13.84, market capitalization USD 128.3 billion. AbbVie (NYSE, USD): price-to-earnings ratio 79.95, market capitalization USD 501.5 billion. Pfizer (NYSE, USD): price-to-earnings ratio 39.99, market capitalization USD 172.4 billion.
Stock trades after hours
The combination of a USD 64.88 consensus target, second-quarter revenue growth of 5.70 percent and the October 29 reporting date gives investors three concrete reference points before the next earnings release. The primary-market valuation remains lower than the two peer multiples listed above.
Bristol Myers Squibb was trading at EUR 55.98 at Lang & Schwarz on October 22, 2026 at 6:19 p.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Bristol Myers Squibb stock at a glance
- Company: Bristol-Myers Squibb Company
- ISIN: US1101221083
- WKN: 850501
- Ticker: BMY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 22, 2026, 6:19 p.m. CEST): EUR 55.98
- Market capitalization: USD 128.3 billion (as of October 22, 2026)
- 52-week range: USD 42.52-68.64 (as of October 22, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
Market context: Market report S&P 500.
